Quoin Pharmaceuticals Receives FDA Orphan Drug Designation for QRX003 in Netherton Syndrome Treatment
Key Insights
Quoin Pharmaceuticals announced that the FDA has granted Orphan Drug Designation to QRX003, its lead product candidate for treating Netherton Syndrome (search).
The FDA designation follows a similar Orphan Drug Designation previously granted by the European Medicines Agency (search) in May 2025.
QRX003 lotion is currently being evaluated in two late-stage whole body pivotal clinical trials with enrollment completion expected in Q1 2026.
Quoin Pharmaceuticals (QNRX) has received FDA Orphan Drug Designation for its lead product candidate QRX003, a topical lotion being developed for the treatment of Netherton Syndrome (search). The regulatory milestone drove shares up 8% in pre-market trading on Tuesday.
Dual Regulatory Recognition
The FDA designation represents the second major regulatory recognition for QRX003, following the European Medicines Agency (search)'s grant of Orphan Drug Designation in May 2025. This dual orphan drug status provides Quoin with significant regulatory advantages in both major markets, including market exclusivity periods and potential fee reductions for regulatory submissions.
Advanced Clinical Development Program
QRX003 lotion is currently being evaluated in two late-stage whole body pivotal clinical trials specifically designed for Netherton Syndrome (search) patients. The company has outlined a clear development timeline with enrollment completion expected in the first quarter of 2026.
According to the company's projections, top-line data from these pivotal trials is anticipated in the second half of 2026, with New Drug Application (NDA) submission planned for later in the same year. This timeline positions QRX003 for potential market entry in the near term, pending successful trial outcomes and regulatory approval.
Market Response
The FDA's orphan drug designation announcement generated immediate investor interest, with Quoin Pharmaceuticals shares rising 8% in pre-market trading. This market response reflects the significance of orphan drug designations in providing regulatory and commercial advantages for rare disease treatments.
The orphan drug pathway offers expedited review processes and extended market exclusivity, making it particularly valuable for companies developing treatments for rare conditions like Netherton Syndrome (search).